symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
GHRS,7.95,0.837924,80668,413565360,0,5.7-14.64,-0.09,GH Research PLC,USD,0001855129,IE000GID8VI0,G3855L106,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.ghres.com,"GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.",Dr. Theis  Terwey M.D.,Healthcare,IE,32,353 1 437 8443,28 Baggot Street Lower,Dublin,,D02 NX43,,0,https://financialmodelingprep.com/image-stock/GHRS.png,2021-06-25,False,False,True,False,False
